At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Check out the companies making headlines in midday trading. Fortinet — Shares jumped more than 7% after TD Cowen upgraded the cybersecurity stock to buy from hold, saying rising memory prices won't ...

The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower ...

You cannot make a return on investment if you don’t have access to the U.S. market," CEO Stéphane Bancel said. In other news, the chairman of the Advisory Committee on Immunization Practices suggested ...

Moderna ( MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back against immunizations.

The comments from Moderna CEO Stéphane Bancel comments are some of his strongest yet about the difficulties that vaccine ...

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.

Moderna CEO Stephane Bancel says the company does not plan to invest in late-stage vaccine trials because of growing scrutiny ...

COVID pivot at Davos, betting on personalised mRNA cancer therapies, new vaccine launches, and AI-led drug development to ...

L-Nutra Inc., the world's first nutri-technology company advancing science-driven nutrition for longevity and nutrition as medicine, announced today a $36.5 million investment in its Series D funding ...

Bank of America compiled a list of stocks that hedge funds are betting against the most. On the S&P 500 (SPY) (IVV) (VOO), ...